H. Lee Moffitt Cancer Center & Research Institute

H. Lee Moffitt Cancer Center & Research Institute

The H. Lee Moffitt Cancer Center & Research Institute was founded in 1986 by former Florida House Speaker H. Lee Moffitt, opening on the University of South Florida's Tampa campus as a state-supported non-profit. Moffitt holds the National Cancer Institute's Comprehensive Cancer Center designation, a credential shared by only 57 institutions nationwide, and serves as a member of the National Comprehensive Cancer Network. Its governance sits with a board chaired by Robert Rothman, while Patrick Hwu, a prominent immunotherapy researcher, has served as president and CEO since 2020. Moffitt's asset base is not a traditional diversified endowment but a hybrid of state appropriations, philanthropic gifts, and commercialization revenue. The institute's foundation, H. Lee Moffitt Cancer Center & Research Institute Foundation Inc., channels donor capital into research programs, clinical trials, and capital projects including the 775-acre Speros FL campus in Pasco County. M2Gen, the informatics subsidiary launched with Merck & Co., created the Oncology Research Information Exchange Network (ORIEN), a data-sharing consortium that pairs longitudinal patient records with genomic sequencing across multiple cancer centers. The institute holds real assets across six Tampa-area properties, including a dedicated business center and outpatient facilities at International Plaza and Wesley Chapel. Team scale is not publicly consolidated, but Moffitt employs over 8,000 staff including 800-plus research faculty, making it one of Tampa Bay's largest employers. The institute participates in industry alliances including the Alliance of Dedicated Cancer Centers. Board member Allison Casper Adams maintains a YPO affiliation, connecting the non-profit to a peer network of executives. In March 2024, Moffitt announced a partnership with a consortium of 10 other cancer centers to accelerate CAR T-cell therapy manufacturing through a shared supply-chain network (per public record). Unlike a conventional family office or university endowment, Moffitt's investment function is embedded entirely within a disease-focused mission — its capital deployment, whether through real estate, research partnerships, or clinical infrastructure, exists solely to compress the timeline from lab discovery to patient treatment. This single-mandate structure eliminates the asset-liability tension that shapes most institutional portfolios, making Moffitt's capital allocation a pure derivative of oncology strategy rather than a return-seeking exercise.